BioCentury
ARTICLE | Clinical News

CDX-014: Phase I/II started

July 25, 2016 7:00 AM UTC

Celldex began an open-label, U.S. Phase I/II trial to evaluate CDX-014 every 3 weeks in about 47 patients with clear cell or papillary RCC and progressed disease after >=2 prior therapies, including 1...